Financial Results - Q4 FY26 (₹ Lakhs)
- Total Income: ₹3,551.91 lakhs (compared to ₹64.02 lakhs in Q4 FY25) - YoY growth of 5,448.13%
- EBITDA: ₹145.24 lakhs (compared to ₹39.81 lakhs in Q4 FY25) - YoY growth of 264.83%
- PAT: ₹106.33 lakhs (compared to ₹39.36 lakhs in Q4 FY25) - YoY growth of 170.15%
- EPS: ₹0.45 (compared to ₹0.21 in Q4 FY25) - YoY growth of 114.29%
Financial Results - FY26 (₹ Lakhs)
- Total Income: ₹9,323.27 lakhs (compared to ₹64.02 lakhs in FY25) - YoY growth of 14,463.06%
- EBITDA: ₹582.18 lakhs (compared to negative ₹107.78 lakhs in FY25) - Turned positive
- PAT: ₹495.98 lakhs (compared to negative ₹108.56 lakhs in FY25) - Turned positive
- EPS: ₹2.09 (compared to negative ₹0.99 in FY25) - Turned positive
Strategic Expansion Initiatives
1. Pharmaceutical Manufacturing & Marketing Expansion
- Expansion of branded generic & generic pharmaceutical manufacturing and marketing business
- Execution through strategic channel partners arranged by "Mr. Franchise"
- Phase 1 will focus on strengthening presence across South India
2. Defence & AI Expansion
- Strategic opportunities assessed in AI-led defence manufacturing and advanced technology-driven sectors
- Company to initiate DGFT (Directorate General of Foreign Trade) approval process for obtaining SCOMET (Special Chemicals, Organisms, Materials, Equipment and Technologies) License
- AI & Defence Technology R&D facility to be established at Cactus TECCI Park, Chennai
3. Strategic Outlook
- Pharma expansion aims to strengthen presence in high-growth therapeutic markets and improve healthcare access
- AI & defence initiative aims to position Company in advanced manufacturing and national security technologies
Management Commentary
Mr. N. Aravind, Managing Director, stated that FY26 represented a turnaround year with decisive execution, accelerated growth, and strategic transformation. He highlighted the exceptional YoY growth of 14,463.06% in total income to ₹93.23 crore and the transition from losses to profitability with EBITDA of ₹5.82 crore and PAT of ₹4.96 crore. The management emphasized building a future-ready pharmaceutical platform driven by innovation, quality, and strategic expansion, with focus on specialty formulations, injectables, and APIs.
Company Description
Kabra Drugs Limited is a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs. The company operates with WHO-GMP aligned systems and advanced manufacturing capabilities, maintaining focus on quality, integrity, and responsible growth.
Disclaimer
The document contains forward-looking statements subject to risks and uncertainties including government actions, local/political/economic developments, technological risks, and other factors that could cause actual results to differ materially. The company undertakes no obligation to publicly update these forward-looking statements.